A single dose, three-arm, placebo-controlled, phase I study of the bradykinin B2 receptor antagonist Anatibant (LF16-0687Ms) in patients with severe traumatic brain injury.

Marmarou, Anthony; Guy, Martine; Murphey, Laine; Roy, Francis; Layani, Laure; Combal, Jean-Philippe; Marquer, Claude

Marmarou, Anthony; Guy, Martine; Murphey, Laine; Roy, Francis; Layani, Laure; Combal, Jean-Philippe; Marquer, Claude.

Affiliation

Marmarou A; American Brain Injury Consortium, ABIC Technical Center, Old City Hall Suite 235, 1001 East Broad Street, Richmond, VA 23298-0449, USA.

J Neurotrauma ; 22(12): 1444-55, 2005 Dec.

Article in En | MEDLINE | ID: mdl-16379582

Subject(s)

Bradykinin B2 Receptor Antagonists; Brain Injuries/drug therapy; Quinolines/adverse effects; Quinolines/pharmacokinetics; Adolescent; Adult; Aged; Area Under Curve; Bradykinin/blood; Bradykinin/cerebrospinal fluid; Bradykinin/drug effects; Double-Blind Method; Female; Glasgow Outcome Scale; Half-Life; Humans; Male; Middle Aged; Peptide Fragments/blood; Peptide Fragments/cerebrospinal fluid; Peptide Fragments/drug effects; Pilot Projects

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Quinolines / Brain Injuries / Bradykinin B2 Receptor Antagonists Type of study: Clinical_trials / Prognostic_studies Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: J Neurotrauma Journal subject: NEUROLOGIA / TRAUMATOLOGIA Year: 2005 Document type: Article Affiliation country: United States Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links